Wheeler Bio Announces Grand Opening of Biomanufacturing Facility

Wheeler Bio, a contract development and manufacturing organization (CDMO) for next-gen protein therapeutics, announced today the grand opening of their state-of-the-art drug substance Current Good Manufacturing Practices (CGMP) facility inside the Ziggurat building (Echo Investment Capital) in Oklahoma City, OK.

Wheeler Bio opens downtown OKC facility

A biotech startup marked the grand opening of its state-of-the-art drug substance Current Good Manufacturing Practice facility Thursday with a ribbon-cutting ceremony downtown.

Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact

Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.